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Consequencesof Antigenic Diversity of Bovine Viral Diarrhea Virus
E.TravisLlttledlke,StevenR.Bolin,andJulia F.Ridpath'"
Introduction
Two mainbiotypesof bovineviraldiarrheavirus(BVDV)
havebeenidentifiedbasedontheirabilitytocausechanges
in tissueculturecells. The cytopathicbiotypemultipliesin
tissuecultureand kills cells, whilethe noncytopathicbio-
typeslowlymultipliesin tissuecultureand has muchless
abilityto kill tissue culturecells. In general,cytopathic
BVDV biotypescause acute infectionsthatoften kill the
bovine fetus, while noncytopathicBVDV biotypesoften
resultin chronicinfectionof thefetuswhich,subsequently,
developsincalvesandadultsthatcarryandshednoncyto-
pathicvirusesathighlevelsfortherestof theirlives.
Previousstudieshaveindicatedthatcytopathicandnon-
cytopathicvirusesareantigenicallysimilar. Also,aftervac-
cinationof cattlewithmodified-liveor killedBVDV vaccines,
antibodiesare inducedthat neutralizea broad range of
BVDV. However, very significant antigenic diversityamong
BVDV has been described. Also, studies indicated that
some neutralizing antibodies from cattle that have recov-
ered from BVDV react differentlywith several BVD isolates.
In addition, monoclonal antibodies developed against spe-
cific BVDV isolates can differentiate BVDV into several
groups and, when cattle which are persistently infectedwith
noncytopathic BVDV are challenged with cytopathic BVDV,
the antibodies they produce have a very narrow range of
viral neutralizingactivity.
Thus, some antigenic diversityamong BVDV, as detected
by neutralizationtests, is well established. However, there
is littleinformationthatshows the practical consequences of
this antigenicdiversityrelativeto the disease in cattle.
The primary purpose of this study was to identifycattle in
MARC's herd that were persistently infectedwith BVDV and
test the isolates of BVDV from the MARC herd to determine
if these natural field viruses could be neutralized by serum
obtained from MARC cows vaccinated with killed BVDV.
Procedure
Sourceofsera. Serum was obtained over a 5-wk period
in the fallof 1988from5,726cows maintainedas a semi-
closedherdon pasture.At thattime,theherdhadbeenon
a killedvirusvaccinationprogramfor BVD for morethan7
years. The vaccineusedwas of bovine-celloriginandcon-
tainedtheSingerisolateof cytopathicBVDV. The vaccina-
tionprogramconsistedof calfhoodvaccinationwiththefirst
dose given 1 mo before weaningand the second dose
given4 wk laterat thetimeof weaning. Thereafter,cows
were revaccinatedwitha singledose of vaccine2 to 3 wk
beforebreeding. Approximately,80% of cows calved in
AprilandMayandtheremaining20%calvedinAugustand
September.At the timesamplesof serumwereobtained,
cows calvingin the springwereat approximately3 mo of
gestationandhadbeenvaccinatedapproximately4 mopre-
viously. Cows thatcalvedin the latesummerhadcalved
approximately2 mo previously and were vaccinated
approximately12 mo previously.The herdwas managed
as severalgroupsof varyingnumbersmaintainedon sepa-
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rate pastures. At weaning, calves from all groups were
moved to a feedlot. Performance of a calf in the feedlot was
one of the criteria used to select herd replacements and cull
dams. The replacement rate for the herd was approxi-
mately20% per year.
Viral neutralization tests. Sera were tested for neutraliz-
ing antibodies against one or more of the following viruses:
cytopathic viral isolates BVD-TGAC and BVD-Singer, and
noncytopathic viral isolates BVD-3659, BVD-2541, BVD-
9789, BVD-NEB, BVD-7443, BVD-639, and BVD-VM.
Noncytopathic viruses 9789, NEB, 7443, and VM were iso-
lated from persistentlyinfectedcattle, BVD-639 was isolated
from the uterus of a cow that aborted, and BVD-3659 and
BVD-2541 were isolated from persistently infected cattle
identifiedduring this study. With the exception of BVD-3659
and BVD-2541, the viruses used were antigenicallydistinct
from each other when tested against a panel of monoclonal
antibodies that had neutralizingactivities. Viruses 3659 and
2541 were antigenically similar to each other, but distinct
from the otherviruses.
Neutralization tests against BVD-TGAC virus were per-
formed on all samples of serum. Those samples of serum
that had neutralized antibody titers of less than 2, 2, 4, or 8
were tested for neutralizing antibody titer against BVD-
Singer virus. In addition, 18 selected samples of serum that
had neutralizedantibodytitersof less than 2, 2, or 4 against
BVD- TGAC virus were tested for neutralizing antibodies
against the aforementioned seven noncytopathic BVD
viruses. All samples of serum (n=56)that had neutralized
antibodytitersof eight against BVD-TGAC virus were tested
for neutralizing antibodies against noncytopathicBVD-3659
virus.
Immunoprecipitation. In selected samples of serum from
killed virus vaccinates that had neutralizedantibody titers of
less than 2 to 256 against BVD-TGAC virus, antibody speci-
ficity for polypeptides induced by BVD-Singer virus (vaccine
virus) was identified by immunoprecipitation. For compari-
son, viral induced polypeptides were immunoprecipitated
with samples of serum obtained from modified-live virus
vaccinates that had neutralizing titers of 2 to 16 against
BVD-TGAC virus.
Results
Viruswas isolatedfrom3 of 448samplesof serumthat
had neutralizedantibodytitersof 64 or less againstBVD-
TGAC virus(Table1). Inthosethreesamplesof serum,the
neutralizingantibodytitersagainstBVD-TGAC viruswere
lessthan2, 2, and32. The correspondingneutralizinganti-
bodytitersagainstBVD-Singerviruswere32,64, and256.
Persistent infectionwas subsequentlyconfirmedin two
cows (ages 2 and 3 yr) by isolationof virus (designated
BVD-3659andBVD-2541)froma secondsampleof serum
obtainedat least4 wk beforeor aftertheoriginalsampleof
serum. Dueto poorperformance,a thirdcow(2 yr of age)
hadbeensoldsoonaftertheoriginalsampleof serumwas
obtained.Itwas notpossibleto confirmpersistentinfection
in thatcow. Viruswas notisolatedfromseraobtainedfrom
siblingsof one persistentlyinfectedcow or the damof the
otherpersistentlyinfectedcow.
Neutralizingantibodytitersof fouror less againstBVD-
TGAC virusweredetectedin samplesof serumobtained
from 91 and 40 cows thatcalved in the fall and spring,
respectively.In eachof those131samplesof serum,neu-
tralizing antibodytiters against BVD-Singer virus were
greaterthanthe correspondingneutralizingantibodytiters
againstBVD-TGAC virus(Table1). Fromthose 131sam-
plesof serum,18wereselectedandfurthertestedfor neu-
tralizing antibodies against seven noncytopathicBVD
viruses. None of these 18 samplesof serumcontained
neutralizingantibodiesagainst all seven noncytopathic
viruses(Table2). NoncytopathicBVD-3659viruswas not
neutralizedby anyof the selectedsamplesof serum. The
BVD-3659virus was neutralizedby 18 of 56 samplesof
serumthathad neutralizedantibodytitersof eightagainst
BVD-TGACvirus(datanotshown).
Conclusion
Althoughthe herdsurveyedin thisstudyhadbeenon a
killedBVDV vaccinationprogramfor 7 yr, twopersistently
infectedcowswereidentified.PersistentBVDV infectionis
lifelongand occurs in calves born to damsthathave an
acute,transientviralinfectionduringthefirst4 moofgesta-
tion or to dams thatare themselvespersistentlyinfected.
The twopersistentlyinfectedcowslikelyrepresentedfailure
ofvaccinationto protectagainstfetalinfectionundernatural
conditions. That finding supportedprevious studies in
whichexperimental,killedBVDV vaccinesfailedto prevent
transplacentaltransmissionof virusin challenged,exposed
cows.
Failure of vaccinationto protectthe fetus mightbe
explainedby antigenicdifferencesamongBVD viruses. In
severalserafromthisherd,thetiterof neutralizingantibod-
ies againstthevaccineviruswas relativelyhigh(64to 256);
however,severalisolatesof BVD viruswere identifiedthat
escapedneutralizationby those same sera. Those data
clearly indicateantigenicdiversityamong BVD viruses.
Includedamongthevirusesthatescapedneutralizationwere
noncytopathicvirusesBVD-3659and BVD-2541thatwere
isolatedfrompersistentlyinfectedcows in thisherd. Thus,
the persistentlyinfectedcows likelyrepresenteda practical
consequenceofantigenicdiversityamongBVDviruses.
Naturaldecayof viral-specificantibodylikelycontributed
to the lack of detectableantibodiesagainstcertainBVD
viruses. Data from this study support this hypothesis.
Approximately,80%of thecowsweregivena boosterdose
of vaccine4 mo beforesamplesof serawereobtainedand
theremaining20%ofcowswereboosteredwithvaccine12
mo beforesampling. A disproportionatelyhigh91 of 131
samplesof serum(70%)thathadneutralizingantibodytiters
of fouror lessagainstBVD-TGAC viruswereobtainedfrom
cows vaccinated12 mo beforesampling. Thus, failureto
detectneutralizingantibodiesagainstcertainBVD viruses
severalmoaftervaccinationmayhavebeenattributableto
viralantigenicdiversityandnaturaldecayofantibodies.
----
On thebasisof thelargenumberof samplesof serathat
had high titersof neutralizingantibodiesagainsta BVD
virusantigenicallydistinctfromthekilledvaccinevirus,and
on thepatternof immunoprecipitatedviral-inducedpolypep-
tidesassociatedwiththosesera,we speculatethatmostof
the cattlein this herd had been infectedwith BVD virus.
Identificationof onlytwo persistentlyinfectedcows might
seemtrivial;however,therateof persistentinfectionproba-
blywouldhavebeenhigherif newborncalvesweretested
insteadof cows. Subsequentto completionof this study,
eightcalvesinthisherd(approximately2 yrold)wereidenti-
fied as persistentlyinfectedwith BVD virus. The persis-
tentlyinfectedcattlein this herdlikelywerebornto vacci-
natedcows thatwere infectedwithfieldvirusduringearly
gestation.ConsequencesofantigenicdiversityamongBVD
virusesarenotlikelylimitedto fetalinfectionsinvaccinated
dams. Newborncalves with colostralantibodyor vacci-
nated feedlot calves might be susceptible to disease
inducedbycertainantigenicvariantsof BVDvirus.
Table 1-Dlstrlbutlon of neutralizingantibodytiters
(-log2)againstbovineviral diarrhea(BVD)-TGAC
virusInall samplesof serumandrangeof titersand
geometricmeantiters of neutralizingantibodies
againstBVD-SlngervirusIn samplesof serumthat
hadneutralizedantibodytitersof three(-log2)or less
againstBVD-TGACvirus
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Geometricmean Rangeof neutralizing
Number Neutralizingantibody titersto antibodytitersto
ofsera titertoTGAC virus Singervirus Singervirus
48 0 4.09 1 to 8
42 1 5.25 3 to 8
41 2 6.11 3 to 8
56 3 5.21 3 to 8
61 4 ND ND
70 5 ND ND
130 6 ND ND
253 7 ND ND
5,025 8 ND ND
ND.Notdone.
---- -------
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Table2-Neutrallzlngantibodytiters(-log2)In selectseraagainstbovineviraldiarrhea(BVD)-TGACvirus,corre-
spondingtitersof neutralizingantibodiesagainstBVD-Slngervirus,andpresence(+)or absence(-)of detectable
concentrationsofneutralizingantibodiesagainstsevenantlgenlcallydistinctnoncytopathlcBVDviruses
Neutralizing
antibodytiter Neutralizingactivityagainst
TGAC Singer
noncytopathicviruses.
virus virus 3659b 2541b 9789 NEB 7443 639 VM
0 1
0 1 - - - - + +
0 3 - - - - - +
0 4
0 6
0 6 - - - - + + +
0 7 - - - - - - +
0 7 - - - + + - +
0 8 - - - - +
1 7 - - - + + + +
1 7 - + + + + + +
1 8 - - - - - + +
1 8 - - - + + + +
2 3 - - - - - - +
2 6 - + + + + + +
2 8 - - - + + + +
2 8 - - + + + + +
2 8 - + - + + + +
·Serumwasdiluted1:1wi1hfluidcon1ainingvirus.
b Viralisola1esfromMARC herd.
